Tower Semiconductor Announces Medical Chip Development With Chinese Biotech Company Axbio
Tower stated the device, which is intended for blood test analyses, is planned to go into production in mid-2019
The chip, developed based on Tower's 65nm RFCMOS platform, is a microfluidics Bio/CMOS device for molecular in vitro diagnostics. Tower said the device, which is intended for blood test analyses, is planned to go into production in mid-2019.
A slowdown in the mobile chip market cut Tower's profit over the past year, leading the company to branch into other, less impacted domains. The company gained 10% on Nasdaq since publishing in February fourth quarter and full year earnings report for the fiscal year 2018, which though less than stellar still exceeded analyst expectations.